European Institute of Oncology Reports Findings in Disease Progression (Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III ...)

Media coverage

• Title	European Institute of Oncology Reports Findings in Disease Progression (Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III ...)
  Media name/outlet	Chemicals & Chemistry Daily
  Country/Territory	United States
  Date	11/23/23
  Persons	Y. Lynn Wang